241 related articles for article (PubMed ID: 16322683)
1. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy.
Blagosklonny MV
Cancer Biol Ther; 2005 Dec; 4(12):1307-10. PubMed ID: 16322683
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
3. Napoleone Ferrara and the saga of vascular endothelial growth factor.
Ribatti D
Endothelium; 2008; 15(1):1-8. PubMed ID: 18568940
[TBL] [Abstract][Full Text] [Related]
4. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of antiangiogenic therapies.
Hudis CA
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):26-31. PubMed ID: 15934500
[TBL] [Abstract][Full Text] [Related]
7. Targeting angiogenesis in bladder cancer.
Elfiky AA; Rosenberg JE
Curr Oncol Rep; 2009 May; 11(3):244-9. PubMed ID: 19336017
[TBL] [Abstract][Full Text] [Related]
8. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
9. From theoretical synergy to clinical supra-additive toxicity.
Soria JC; Massard C; Izzedine H
J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
[No Abstract] [Full Text] [Related]
10. [Effect of vascular endothelial growth factor antibody Avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice].
Wang N; Wang B; Wang YJ
Ai Zheng; 2006 Sep; 25(9):1076-81. PubMed ID: 16965645
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab (Avastin).
Mukherji SK
AJNR Am J Neuroradiol; 2010 Feb; 31(2):235-6. PubMed ID: 20037132
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
13. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
14. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
15. The possible role of chemotherapy in antiangiogenic drug resistance.
Bocci G; Loupakis F
Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
[TBL] [Abstract][Full Text] [Related]
16. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma.
Reiners KS; Gossmann A; von Strandmann EP; Böll B; Engert A; Borchmann P
J Immunother; 2009 Jun; 32(5):508-12. PubMed ID: 19609243
[TBL] [Abstract][Full Text] [Related]
17. Future directions with angiogenesis inhibitors in colorectal cancer.
Bilenker JH; Haller DG
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S86-93. PubMed ID: 15479485
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor and bevacitumab in breast cancer.
Bando H
Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
[TBL] [Abstract][Full Text] [Related]
19. [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
Cai YJ; Zheng DY; Luo RC; Chen JZ; Li AM; Xi JL; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):647-9. PubMed ID: 17545079
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
